U.S. Markets close in 2 hrs 47 mins
  • S&P 500

    4,410.59
    +43.11 (+0.99%)
     
  • Dow 30

    35,058.99
    +235.64 (+0.68%)
     
  • Nasdaq

    14,823.73
    +139.14 (+0.95%)
     
  • Russell 2000

    2,200.13
    +0.66 (+0.03%)
     
  • Crude Oil

    71.92
    +0.01 (+0.01%)
     
  • Gold

    1,802.50
    -2.90 (-0.16%)
     
  • Silver

    25.27
    -0.11 (-0.42%)
     
  • EUR/USD

    1.1774
    +0.0001 (+0.0118%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • Vix

    17.26
    -0.43 (-2.43%)
     
  • GBP/USD

    1.3761
    -0.0007 (-0.0495%)
     
  • USD/JPY

    110.5200
    +0.4050 (+0.3678%)
     
  • BTC-USD

    32,116.91
    -321.99 (-0.99%)
     
  • CMC Crypto 200

    775.91
    -17.83 (-2.25%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?

·4 min read
How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Moderna (NASDAQ: MRNA) currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. Pfizer (NYSE: PFE) is Moderna's chief rival in the COVID-19 vaccine market. Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion.